NCT02599454 - Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

January 22, 2020

Study Completion Date

December 31, 2023

Conditions

Stage I Non-Small Cell Lung Cancer

Interventions

DRUG

Atezolizumab

Into the vein Day 1 every 3 weeks for 6 cycles

RADIATION

Stereotactic Body Radiation Therapy

Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors

Trial Locations (2)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

94535-1800

David Grant United States Air Force Medical Center, Travis Air Force Base